Advocacy intelligence hub — real-time data for patient organizations
Kedrion S.p.A. — PHASE3
Heinrich-Heine University, Duesseldorf
argenx — PHASE3
Immunovant Sciences GmbH — PHASE2
University of Ulm
argenx — PHASE3
University of Erlangen-Nürnberg Medical School
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Foundation grants
Copay cards
Foundation Grants1
HealthWell Foundation — Chronic inflammatory demyelinating polyneuropathy
HealthWell Foundation
Copay Assistance3
Hizentra
CSL Behring
HyQvia
Takeda Development Center Americas, Inc.
Gamunex-C
Grifols Therapeutics, Inc.
Vyvgart Hytrulo
(EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT))Orphan drugargenx US
Neonatal Fc Receptor Blocker [EPC]
12.1 Mechanism of Action VYVGART HYTRULO is a coformulation of efgartigimod alfa and hyaluronidase. Efgartigimod alfa is a human IgG1 antibody fragmen...
HyQvia
(Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase)Orphan drugTakeda Development Center Americas, Inc.
Hizentra
(Immune Globulin Subcutaneous (Human), 20% Liquid)Orphan drugCSL Behring
Browse all Chronic inflammatory demyelinating polyneuropathy news →
Eduardo NOBILE-ORAZIO, MD
IRCCS Instituto Clinico Humanitas, Milano, Italy
Jeffrey A Allen, MD
University of Minnesota
Pietro Emiliano Doneddu, MD
Humanitas Research Institute
Urielle Desalbres
AP-HM
Wolfgang Frenzel, MD
International Medical Director
Johannes Dorst, Prof
University of Ulm
View all Chronic inflammatory demyelinating polyneuropathy specialists →